Literature DB >> 32169378

Neonatal thymectomy in children-accelerating the immunologic clock?

Angela Deya-Martinez1, Aisling M Flinn2, Andrew R Gennery3.   

Abstract

The thymus is critical for central tolerance and diverse T-lymphocyte repertoire development, to provide lifelong defense against pathogens while maintaining self-tolerance. Peak thymic output occurs in utero, during infancy, and in early childhood, diminishing throughout life. Infants with congenital heart disease requiring sternotomy often undergo thymectomy to clear the surgical field. The long-term effects of early thymectomy are just being appreciated. Many patients remain asymptomatic despite immunologic findings mirroring those of immunosenescence. Few develop increased infection or lymphoreticular malignancy risk. When considering the effects of infant thymectomy, patients with partial DiGeorge syndrome or hypomorphic recombination-activating gene (RAG) mutations may be instructive. These patients are lymphocytopenic, with increased early-onset infection and autoimmunity risk that is not seen in most patients who underwent thymectomy during infancy. The thymic structure of patients with partial DiGeorge syndrome or hypomorphic RAG is abnormal, with disrupted architecture inclining to perturbation of central tolerance. Similar findings may be seen in patients with myasthenia gravis, although disrupted peripheral tolerance may play a greater role in autoimmunity development. In conclusion, thymectomy during infancy may increase future risk of infection or autoimmunity, with premature immunosenescence mediated through disruption of central and peripheral tolerance mechanisms initiated by early cessation or diminution of thymic output. Ideally, some thymic tissue should be preserved at the time of surgery.
Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  T-lymphocyte; Thymus; immunodeficiency; immunosenescence; neonatal thymectomy

Mesh:

Year:  2020        PMID: 32169378     DOI: 10.1016/j.jaci.2020.02.028

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

1.  T Cell Response to Influenza Vaccination Remains Intact in Adults with Congenital Heart Disease Who Underwent Early Thymectomy.

Authors:  David M Leone; Hong-Jai Park; Serhan Unlu; Michelle Gurvitz; Insoo Kang; Robert W Elder
Journal:  Int J Cardiol Congenit Heart Dis       Date:  2022-03-25

2.  Medical Therapies for Heart Failure in Hypoplastic Left Heart Syndrome.

Authors:  Angela N Baybayon-Grandgeorge; Ashley E Pietra; Shelley D Miyamoto; Anastacia M Garcia
Journal:  J Cardiovasc Dev Dis       Date:  2022-05-12

3.  Congenital heart disease and the risk of cancer: The importance of understanding associated comorbidities.

Authors:  Erika J Mejia; Joseph W Rossano
Journal:  Lancet Reg Health Eur       Date:  2022-05-28

4.  Relationship Between Severity of T Cell Lymphopenia and Immune Dysregulation in Patients with DiGeorge Syndrome (22q11.2 Deletions and/or Related TBX1 Mutations): a USIDNET Study.

Authors:  Deepti R Deshpande; Yesim Y Demirdag; Rebecca A Marsh; Kathleen E Sullivan; Jordan S Orange
Journal:  J Clin Immunol       Date:  2020-09-19       Impact factor: 8.317

Review 5.  Current and Future Therapeutic Approaches for Thymic Stromal Cell Defects.

Authors:  Alexandra Y Kreins; Paola Bonfanti; E Graham Davies
Journal:  Front Immunol       Date:  2021-03-18       Impact factor: 7.561

6.  The Presence of a Marked Imbalance Between Regulatory T Cells and Effector T Cells Reveals That Tolerance Mechanisms Could Be Compromised in Heart Transplant Children.

Authors:  Esther Bernaldo-de-Quirós; Jacobo López-Abente; Manuela Camino; Nuria Gil; Esther Panadero; Rocío López-Esteban; Marta Martínez-Bonet; Marjorie Pion; Rafael Correa-Rocha
Journal:  Transplant Direct       Date:  2021-04-23

7.  Case Report: "Primary Immunodeficiency"-Severe Autoimmune Enteropathy in a Pediatric Heart Transplant Recipient Treated With Abatacept and Alemtuzumab.

Authors:  Elizaveta Kalaidina; Elizabeth C Utterson; Deepa Mokshagundam; Mai He; Shalini Shenoy; Megan A Cooper
Journal:  Front Immunol       Date:  2022-04-05       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.